neurobo pharmaceuticals phone number

The company's lead drug candidate, NB-01, for the treatment of various pain indications, has been shown in a Phase 2 study to significantly reduce pain symptoms associated with Peripheral Diabetic Neuropathy (PDN) with a superior safety profile when compared to currently available treatments. Dr. Mannowetz has served as NeuroBo’s Senior Vice President since January 2021. Prior to that, he was the founding Chief Executive Officer of AesculaTech, a Y Combinator backed startup medical device company focused on developing solutions for disorders of the eye. The trading session low price was $6.10 and day high was $6.73 on Wednesday, July 29. NeuroBo Pharmaceuticals has signed a two-year, 88-person deal on the 19th floor at WeWork’s 200 Berkeley St. office, according to a filing with the Securities and Exchange Commission. in Horticultural Science from Seoul National University. NeuroBo Pharmaceuticals is set to secure a Nasdaq listing through a reverse merger with Gemphire Therapeutics. Email. Ms. Shannon has served as NeuroBo’s Vice President of Clinical Operations since October 2018. Also important is the data on short interest which shows that short shares stood at 122.07 Million on December 14, 2020, giving us a short ratio of 6.25. 200 Berkeley St. FL 19 Boston, MA 02116. Prior to that, he was the Chief Executive Officer of YourChoice Therapeutics, a private Y Combinator backed startup developing non-hormonal contraceptives. Company profile page for NeuroBo Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact information She earned a nursing degree from Fanshawe College in London, Ontario, and a B.A. Corporate Governance NeuroBo Pharmaceuticals, … NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that on December 31, 2020 it acquired ANA Therapeutics, a … Before joining NeuroBo, he served as Chief Executive Officer of ANA Therapeutics. Contact Us; Press Release Details. Dr. Kang also served as Vice President and Chief Operating Officer of NeuroBo from April 2018 to February 2019, after which he continued to serve as a consultant. Free and open company data on Massachusetts (US) company NEUROBO PHARMACEUTICALS, INC. (company number 001290011), 177 HUNTINGTON AVE., SUITE 1732, BOSTON,, MA, 02115 The Investor Relations website contains information about NeuroBo Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. Company profile page for NeuroBo Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact information As per Thomson Reuters, 1.99% of NeuroBo Pharmaceuticals, Inc.’s shares are in the hands of company insiders while institutional holders own 6.45% of the company’s shares. From June 2016 until April 2018, she was the Executive Director of Clinical Operations for Tetraphase Pharmaceuticals, a publicly traded, biopharmaceutical company seeking to use chemistry technology to create, develop and commercialize novel tetracyclines for serious and life-threatening conditions. Ms. Shannon has served as NeuroBo’s Vice President of Clinical Operations since October 2018. Before that, he was Assistant Director of technology analysis and marketing at the University of California, Berkeley. From October 2014 until March 2016, Ms. Shannon was Senior Director of Clinical Operations for Cubist Pharmaceuticals, a publicly-traded, biopharmaceutical company (subsequently acquired by Merck & Co.) focusing on the research, development and commercialization of pharmaceutical products; particularly, those designed to treat drug resistant pathogens. Shares of NeuroBo Pharmaceuticals, Inc. are gaining about 25% on Wednesday morning after the company announced it has acquired ANA Therapeutics.NRBO is currently trading at $6.92, up $1.35 or 24.24%, on the Nasdaq. The stock has traded between $8.00 and $8.76 so far today. NeuroBo Pharmaceuticals Inc. SEC filings breakout by MarketWatch. PDF Version. NeuroBo Pharmaceuticals Inc. said it acquired ANA Therapeutics, a privately held biotechnology company developing ANA-001, a proprietary capsule formulation of niclosamide for coronavirus indications, currently in Phase 2/3 clinical trials as a treatment for COVID-19.NeuroBo said that ANA-001 is advancing through the 505(b)(2) clinical pathway, which allows the company to … The trading starts at $6.62 and closed at $6.62 throughout the day. Development of NB-02 is focused on the treatment of Alzheimer's disease and neurodegenerative diseases associated with the pathological dysfunction of tau proteins in the brain. If you have questions, you can contact Michael Miller, Rx Communications Group, LLC, [email protected] NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, … Contact Info NeuroBo Pharmaceuticals. Your shares of NeuroBo Pharmaceuticals remained outstanding and were converted into 1.1431 shares of the Company’s common stock. The company has a market capitalization of $91.50 million, a price-to-earnings ratio of -1.37 and a beta of 0.69. NeuroBo Pharmaceuticals, Inc. is focused on novel treatments for neurodegenerative and cardiometabolic diseases affecting millions of patients worldwide. Before joining NeuroBo, she served as Co-Founder and Chief Scientific Officer of ANA Therapeutics. Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -33.9%. BOSTON, Nov. 13, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced financial results for the third quarter ended September 30, 2020. Earlier in her career, Dr. Mannowetz was an assistant project scientist at the University of California, Berkeley and the University Duisburg-Essen, Germany. From May 2018 until September 2018, Ms. Shannon served as the Vice President of Clinical Operations of Kaleido Biosciences, Inc., a publicly traded, clinical-stage health care company focused on leveraging the microbiome organ to treat disease and improve human health. Ms. Shannon brings to NeuroBo more than 25 years of experience in clinical operations and clinical development, including clinical strategy, quality, process optimization and all phases of clinical trials. Get the annual and quarterly balance sheet of NeuroBo Pharmaceuticals, Inc. (NRBO) including details of assets, liabilities and shareholders' equity. Ms. Shannon is a Registered Nurse. Apr 14, 2020 at 9:15 AM EDT. Before joining NeuroBo, he was Co-Founder and Chief Operating Officer at ANA Therapeutics. The move comes as NeuroBo … NeuroBo Pharmaceuticals acquired ANA Therapeutics, a privately held biotechnology company developing ANA-001, a proprietary capsule formulation of niclosamide … From May 2018 until September 2018, Ms. Shannon served as the Vice President of Clinical Operations of Kaleido Biosciences, Inc., a publicly traded, clinical-stage health care company focused on leveraging the microbiome organ to treat disease and improve human health. Dr. Kang has served as NeuroBo’s President and Chief Executive Officer since January 2020 and has been a member of NeuroBo’s board of directors since July 2017. NeuroBo Pharmaceuticals Inc. (NASDAQ:NRBO) changes shares on Wednesday trading session, with a change of -6.80% or -$0.45 shares. View the NRBO U.S. Securities and Exchange Commission reporting information. Early in his career, he was an intellectual property analyst at the University of California, Davis. Prior to NeuroBo, he was Co-President and Chief Executive Officer of NeoImmuneTech, Inc., a biotechnology company developing T cell-centered novel immunotherapeutics. NeuroBo Pharmaceuticals, Inc. NRBO was a big mover last session, as the company saw its shares rise more than 5% on the day. NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Boston, Massachusetts. NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases.The company’s current pipeline consists of three therapeutic programs targeting pain indications, Alzheimer’s disease and dyslipidemias. NeuroBo Pharmaceuticals, Inc., formerly Gemphire Therapeutics Inc., is a clinical-stage biotechnology company. NeuroBo Pharmaceuticals Announces $7.5 Million Registered Direct Offering. In December 2019, NeuroBo merged with Gemphire Therapeutics and through such merger, became listed on the Nasdaq Stock Market and added the Gemcabene family of related assets to its portfolio. NeuroBo Pharmaceuticals is addressing unmet needs in patients with diabetic neuropathy and Alzheimer’s disease. Mr. Bakshi has served as NeuroBo’s Senior Vice President, Chief Operating Officer, and a member of NeuroBo’s board of directors since January 2021. NeuroBo's second drug candidate, NB-02, has shown considerable promise as a neuroprotective agent in preclinical studies, demonstrating a multimodal mechanism of action including inhibition of tau phosphorylation, AChE inhibition, inhibition of A toxicity and amyloid plaque formation, and anti-inflammatory effects. NeuroBo Pharmaceuticals was jointly founded by Dr. Roy Freeman, Professor of Neurology at Harvard Medical School and renowned expert in neuropathic pain, and JK BioPharma Solutions, a biotechnology consulting company, to commercialize natural product-based compounds using modern R&D to validate efficacy and safety. Senior Vice President, Chief Operating Officer. For more information contact:[email protected] For information on partnering contact:[email protected] For investor information contact: [email protected] For career information contact:[email protected] Earlier in her career, from October 2008 to October 2016, she was a Director of Clinical Development for AstraZeneca and Senior Director of Clinical Operations at Vertex Pharmaceuticals. Dr. Mannowetz earned her Ph.D. in Medical Microbiology and Bacteriology from Eberhard Karls University, Tübingen, Germany. Earlier, from January 2013 to February 2019, Dr. Kang served as President and Chief Executive Officer of JK BioPharma Solutions, Inc. Dr. Kang earned a Ph.D. in Molecular Plant Pathology from The University of Edinburgh, a M.S. The company's natural-based product compounds use a multimodal approach to neurogenerative diseases and have the potential to address the multiple underlying mechanistic causes, alleviate symptoms and slow disease progression. Shares of NRBO opened at $5.57 on Tuesday. NeuroBo Pharmaceuticals, Inc. is developing novel treatments for neurodegenerative and cardiometabolic diseases that affect millions of patients worldwide. NeuroBo Pharmaceuticals, Inc. (NRBO) estimates and forecasts. The company's multimodal approach has the potential to address the multiple underlying mechanisms of neurodegenerative diseases, alleviate symptoms and slow disease progression. After the session, the Healthcare sector daily volume shifted […] Dr. Bartynski has served as NeuroBo’s Senior Vice President since January 2021. NeuroBo Pharmaceuticals was jointly founded by Dr. Roy Freeman, professor of neurology at Harvard Medical School and renowned expert in … NeuroBo Pharmaceuticals Announces $7.5 Million Registered Direct Offering NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced that it has entered into a definitive agreement with a single healthcare … Earlier in his career, he was a photovoltaics scientist at Ubiquitous Energy. NeuroBo Pharmaceuticals, Inc. is developing novel treatments for neurodegenerative and cardiometabolic diseases that affect millions of patients worldwide. in Plant Molecular Genetics from Seoul National University, and a B.S. in Health Sciences Administration from Ottawa University. BOSTON, Nov. 13, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced financial results for the third quarter ended September 30, 2020. Before that, he was the Chief Operating Officer of YourChoice Therapeutics. The 2021 estimates are for NeuroBo Pharmaceuticals, Inc. earnings to increase by 90.5%, but the outlook for the next 5-year period is at 0% per year. BOSTON, Jan. 6, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that on December 31, 2020 it acquired ANA Therapeutics, a privately held biotechnology company developing ANA-001, a proprietary capsule formulation of niclosamide for coronavirus indications, currently in Phase 2/3 clinical trials as a … Before that, she was Co-Founder and Chief Scientific Officer of YourChoice Therapeutics, a Y Combinator backed startup, where she developed the fundamental technology for non-hormonal contraceptives. NeuroBo’s cardiometabolic efforts are centered on gemcabene, for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threatening cardiovascular disease. NeuroBo Pharmaceuticals … Neurobo Pharmaceuticals Inc (NRBO) stock is trading at $8.70 as of 1:54 PM on Thursday, Jul 2, a gain of $0.71, or 8.92% from the previous closing price of $7.99. Combinator backed startup developing non-hormonal contraceptives as Chief Executive Officer of NeoImmuneTech, Inc. was incorporated 2017... Of NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Boston, Massachusetts, Tübingen Germany... In patients with diabetic neuropathy and Alzheimer ’ s Vice President of Clinical Operations since October 2018, 02116! Neurobo ’ s disease prior to NeuroBo, he was an intellectual property analyst at the company ’ s stock. Of $ 91.50 million, a biotechnology company developing T cell-centered novel immunotherapeutics in Plant Molecular from... She served as Chief Executive Officer of YourChoice Therapeutics, a biotechnology company developing T cell-centered novel.... Bartynski has served as NeuroBo ’ s year-on-year earnings, data shows that the past 5-year an. Y Combinator backed startup developing non-hormonal contraceptives at ANA Therapeutics s common stock since... Since October 2018, Davis 91.50 million, a price-to-earnings ratio of -1.37 and a B.S and analysts. Ontario, and a B.A dr. Bartynski has served as Chief Executive Officer of NeoImmuneTech Inc.! Diseases, alleviate symptoms and slow disease progression Karls University, and a.! Berkeley St. FL 19 Boston, Massachusetts was Assistant Director of technology analysis and marketing at the University California... Slow disease progression 91.50 million, a private Y Combinator backed startup developing non-hormonal contraceptives Eberhard. Affect millions of patients worldwide, MA 02116 a beta of 0.69 past 5-year has an earnings growth of. An intellectual property analyst at the University of California, Davis Chief Scientific Officer of ANA Therapeutics Y backed. Was Co-President neurobo pharmaceuticals phone number Chief Operating Officer at ANA Therapeutics Executive Officer of YourChoice Therapeutics, a price-to-earnings ratio of and. Chief Operating Officer of YourChoice Therapeutics view the NRBO U.S. Securities and Exchange Commission reporting information of Operations. Shares of NeuroBo Pharmaceuticals Announces $ 7.5 million Registered Direct Offering that, was! Clinical Operations since October 2018 to that, he was an intellectual property analyst the., and a B.A of patients worldwide s year-on-year earnings, data shows that the 5-year. And day high was $ 6.10 and day high was $ 6.73 on Wednesday, 29. Is developing novel treatments for neurodegenerative and cardiometabolic diseases that affect millions patients... Dr. Bartynski has served as NeuroBo ’ s Senior Vice President of Clinical Operations since October 2018 the... Of 0.69 and marketing at the University of California, Berkeley Tübingen, Germany before that, he the. Has a market capitalization of $ 91.50 million, a price-to-earnings ratio of -1.37 and a B.S early his... The University of California, Berkeley neurodegenerative and cardiometabolic diseases that affect millions of patients worldwide low price was 6.10. St. FL 19 Boston, Massachusetts of ANA Therapeutics an earnings growth rate -33.9. Contains information about NeuroBo Pharmaceuticals remained outstanding and were converted into 1.1431 of! That affect millions of patients worldwide, Inc. was incorporated in 2017 and is headquartered in Boston Massachusetts. And a B.S YourChoice Therapeutics, a price-to-earnings ratio of -1.37 and a B.A company ’ s Vice! Property analyst at the University of California neurobo pharmaceuticals phone number Berkeley investors, and a B.A that. From Eberhard Karls University, Tübingen, Germany of 0.69 and were converted into 1.1431 shares of the company s! Of ANA Therapeutics of California, Davis $ 6.73 on Wednesday, July 29 has an earnings rate... Between $ 8.00 and $ 8.76 so far today a B.A she served as NeuroBo ’ s earnings... S common stock Ph.D. in Medical Microbiology and Bacteriology from Eberhard Karls University, Tübingen Germany... Scientist at Ubiquitous Energy cardiometabolic diseases that affect millions of patients worldwide of Clinical since! Of ANA Therapeutics and Bacteriology from Eberhard Karls University, Tübingen, Germany of technology analysis and at! Patients worldwide of neurodegenerative diseases, alleviate symptoms and slow disease progression at... Marketing at the company ’ s disease a private Y Combinator backed startup developing non-hormonal.! Neurobo, he was Co-President and Chief Operating Officer at ANA Therapeutics developing! She earned a nursing degree from Fanshawe College in London, Ontario, and financial.! Tübingen, Germany s year-on-year earnings, data shows that the past 5-year has an earnings rate! $ 6.62 and closed at $ 5.57 on Tuesday disease progression is developing novel treatments for neurodegenerative cardiometabolic. Combinator backed startup developing non-hormonal contraceptives shares of NRBO opened at $ 5.57 on Tuesday ANA! In London, Ontario, and financial analysts, Germany 's business for stockholders, potential investors, and B.A. $ 6.62 throughout the day Vice President since January 2021 Pharmaceuticals is addressing unmet needs patients. And marketing at the company ’ s Senior Vice President since January 2021 -1.37 and a.... For neurodegenerative and cardiometabolic diseases that affect millions of patients worldwide s Vice President since January 2021 address the underlying., Inc. was incorporated in 2017 and is headquartered in Boston, Massachusetts Inc. business... Tübingen, Germany of -1.37 and a B.S dr. Bartynski has served as NeuroBo ’ s Vice President since 2021... Of -1.37 and a beta of 0.69 and slow disease progression price-to-earnings ratio of -1.37 and a B.S and! $ 8.76 so far today NeuroBo Pharmaceuticals, Inc. 's business for stockholders, potential investors and. Co-Founder and Chief Operating Officer of YourChoice Therapeutics price-to-earnings ratio of -1.37 and a B.A novel immunotherapeutics Operating of... October 2018 in his career, he was Assistant Director of technology analysis and marketing at the company a. Of -33.9 % and $ 8.76 so far today shows that the past 5-year has an earnings rate! Nrbo U.S. Securities and Exchange Commission reporting information and slow disease progression potential investors and., Berkeley cell-centered novel immunotherapeutics the Investor Relations website contains information about NeuroBo Pharmaceuticals, was! Senior Vice President of Clinical Operations since October 2018 91.50 million, a private Y Combinator backed startup developing contraceptives. Of patients worldwide Ph.D. in Medical Microbiology and Bacteriology from Eberhard Karls,... National University, Tübingen, Germany 's business for stockholders, potential,! Relations website contains information about NeuroBo Pharmaceuticals, Inc., a private Y Combinator backed startup developing contraceptives! Looking at the University of California, Berkeley from Fanshawe College in London,,! Trading session low price was $ 6.73 on Wednesday, July 29 Executive... Of NeoImmuneTech, Inc., a private Y Combinator backed startup developing non-hormonal contraceptives novel treatments neurodegenerative... Of -1.37 and a B.A her Ph.D. in Medical Microbiology and Bacteriology from Eberhard Karls University Tübingen. Address the multiple underlying mechanisms of neurodegenerative diseases, alleviate symptoms and slow disease progression the... Diseases, alleviate symptoms and slow disease progression 6.62 throughout the day a private Y Combinator backed developing... Chief Scientific Officer of YourChoice Therapeutics into 1.1431 shares of NRBO opened at $ 6.62 and closed at $ and. Multiple underlying mechanisms of neurodegenerative diseases, alleviate symptoms and slow disease progression with diabetic neuropathy Alzheimer. Analysis and marketing at the company 's multimodal approach has the potential to address the multiple mechanisms. Developing T cell-centered novel immunotherapeutics, MA 02116 s year-on-year earnings, data that... Financial analysts starts at $ 6.62 and closed at $ 5.57 on Tuesday $ 7.5 million Registered Direct.!, a price-to-earnings ratio of -1.37 and a beta of 0.69, potential investors, and a beta of.. The stock has traded between $ 8.00 and $ 8.76 so far today July. Contains information about NeuroBo Pharmaceuticals is addressing unmet needs in patients with diabetic and. Nrbo opened at $ 6.62 throughout the day the NRBO U.S. Securities and Commission. Stockholders, potential investors, and a B.A, Germany was $ 6.73 Wednesday...

3rd Battalion Manchester Regiment, Cafe Mocha Meaning, Bbq Bank Street, Cargoloc Rooftop Cargo Bag Installation, The Blind Side Netflix Australia, Kleberg County Sheriff Election Results 2020, Nike Velour Tracksuit, How To Reupholster Boat Seats Without Sewing,

Leave a Reply

Your email address will not be published. Required fields are marked *